Constellation Pharmaceuticals, Inc.
CNST
CNST was delisted on the 14th of July, 2021.
0 hedge funds and large institutions have $0 invested in Constellation Pharmaceuticals, Inc. in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 153 closing their positions.
100% less funds holding
Funds holding: 153 → 0 (-153)
100% less funds holding in top 10
Funds holding in top 10: 9 → 0 (-9)
100% less capital invested
Capital invested by funds: $1.42B → $0 (-$1.42B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 153
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$108M |
| 2 |
BlackRock
New York
|
-$94M |
| 3 |
CG
Column Group
San Francisco,
California
|
-$88.8M |
| 4 |
PM
Ponoi Management
San Francisco,
California
|
-$63.6M |
| 5 |
OPU
Omni Partners US
Irvine,
California
|
-$61.4M |
CNST Hedge Fund Activity: Q3 2021 in Review
0 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q3 2021, worth a combined $0 — down 100% from $1.42B a quarter earlier.
Sellers outnumbered buyers: 153 funds closed out of CNST and 0 opened new positions — a net loss of 153 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $108M sold.
- 0 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q3 2021, down from 153 in Q2 2021.
- Funds reported $0 of Constellation Pharmaceuticals, Inc. stock for Q3 2021, down 100% quarter-over-quarter.
- 0 funds opened new Constellation Pharmaceuticals, Inc. positions in Q3 2021 and 153 closed out, a net change of -153 holders.
- The largest Constellation Pharmaceuticals, Inc. seller in Q3 2021 was Avoro Capital Advisors, an estimated $108M sold.
Based on aggregated 13F filings for Q3 2021.